Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patients

Lung Cancer

Volumn 75, Issue 2, 2012, Pages 213-216

  Jacot, William ^a,b   Pujol, Jean Louis ^a   Chakra, Mohammad ^a   Molinier, Olivier ^a   Bozonnat, Marie Cécile ^c   Gervais, Radj ^d   Quantin, Xavier ^a  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b Montpellier Cancer Centre   (France)

^c UNIV MONTPELLIER   (France)

^d Caen Cancer Center   (France)

Author keywords

Anthracyclin; Ifosfamide; Relapse; Small cell lung cancer

Indexed keywords

AMRUBICIN; ANTHRACYCLINE DERIVATIVE; EPIRUBICIN; IFOSFAMIDE; MESNA; TENIPOSIDE; TOPOTECAN;

ADULT; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER RELAPSE; CANCER RESISTANCE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; FEBRILE NEUTROPENIA; FEMALE; FUNCTIONAL STATUS; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; EPIRUBICIN; FEMALE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 84855432233     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.07.012     Document Type: Article

References (13)

1. Arriagada R., Kramar A., Le Chevalier T., De Cremoux H. Competing events determining relapse-free survival in limited small-cell lung carcinoma. The French Cancer Centers' Lung Group. J Clin Oncol 1992, 10(March (3)):447-451.
2. Cheng S., Evans W.K., Stys-Norman D., Shepherd F.A. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2007, 2(April (4)):348-354.
3. von Pawel J., Schiller J.H., Shepherd F.A., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999, 17(February (2)):658-667.
4. Huisman C., Postmus P.E., Giaccone G., Smit E.F. Second-line chemotherapy and its evaluation in small cell lung cancer. Cancer Treat Rev 1999, 25(August (4)):199-206.
5. O'Brien M.E., Ciuleanu T.E., Tsekov H., et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006, 24(December (34)):5441-5447.
6. Ettinger D.S. Ifosfamide in the treatment of small cell lung cancer. Semin Oncol 1996, 23(June (3 Suppl. 6)):2-6.
7. Ettinger D.S., Finkelstein D.M., Ritch P.S., Lincoln S.T., Blum R.H. Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588). Lung Cancer 2002, 37(September (3)):311-318.
8. Ettinger D.S., Jotte R., Lorigan P., et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010, 28(May (15)):2598-2603.
9. Brocato N., Bruno M.F., Araujo C.E., et al. Treatment of non-small cell lung cancer with ifosfamide (IFO)+4'-epiadriamycin (EPI)+platinum vs. IFO+EPI: a GETLAC Study. Grupo de Estudio y Tratamiento Latinoamericano del Cancer Study. Oncology 1995, 52(January-February (1)):24-31.
10. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(January (2)):228-247.
11. Eckardt J.R., von Pawel J., Pujol J.L., et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007, 25(May (15)):2086-2092.
12. Jotte R., Conkling P., Reynolds C., et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 2011, 29(January (3)):287-293.
13. Frustaci S., Foladore S., Buonadonna A., et al. Epirubicin and ifosfamide in advanced soft tissue sarcomas. Ann Oncol 1993, 4(September (8)):669-672.